Associated Papers
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
39991480 (PubMed )
Supplement: mmc5.xlsx › Sheet1
Pharmacogenetics of Drug Metabolism: The Role of Gene Polymorphism in the Regulation of Doxorubicin Safety and Efficacy.
Bagdasaryan AA et al.
Cancers, 2022
The genetic landscape of the human solute carrier (SLC) transporter superfamily.
Schaller L et al.
Human Genetics, 2019
Polymorphisms of genes encoding drug transporters or cytochrome P450 enzymes and association with clinical response in cancer patients: a systematic review.
Kulma I et al.
Cancer Chemotherapy and Pharmacology, 2019
Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.
Tecza K et al.
Oncotarget, 2018
Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?
Magdy T et al.
Pharmacology & Therapeutics, 2016
Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.
Chen S et al.
Drug Metabolism Reviews, 2016
Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations.
Cocca M et al.
Journal of Translational Medicine, 2016
26801900 (PubMed )
Supplement: 12967_2016_778_MOESM3_ESM.xls › Sheet1
Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine.
Simeon V et al.
International Journal of Molecular Sciences, 2015
26263974 (PubMed )
Supplement: ijms-16-17514-s001.pdf
Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients.
Voon PJ et al.
British Journal of Clinical Pharmacology, 2013
Exploratory data from complete genomes of familial alzheimer disease age-at-onset outliers.
Lalli MA et al.
Human Mutation, 2012
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
Bray J et al.
British Journal of Cancer, 2010
Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients.
Lal S et al.
Pharmacogenomics, 2007
Select a paper to view details